Login

Switch On Your HIV Smarts.

The Link Between Protease Inhibitors and Cancer

The Link Between Protease Inhibitors and Cancer

, by Emily Newman

A recent study reports an association between protease inhibitors and cancer. What do these findings mean for people now taking a PI-based regimen? Read More

Who’s been using PEP—and would they benefit from PrEP?

Who’s been using PEP—and would they benefit from PrEP?

, by Emily Newman

An analysis of 15 years of clinical data shows an increase in the use of post-exposure prophylaxis (PEP) to prevent HIV, and could have implications for PrEP use. Read More

Risk of AIDS, Serious Illness and Death Reduced by 53% with Early ART

Risk of AIDS, Serious Illness and Death Reduced by 53% with Early ART

, by Emily Newman

The first-ever large randomized controlled trial investigating the impact of early HIV treatment released preliminary results showing that people with HIV should start ART regardless of CD4 count. Read More

Capping Coinsurance Payments for PrEP and HIV Meds

Capping Coinsurance Payments for PrEP and HIV Meds

, by Emily Newman

Covered California will soon vote on capping the amount consumers have to pay for drugs in the “specialty” tier. Two experts explain what this will mean for people paying for HIV medications and Truvada for PrEP. Read More

DHHS: Atripla No Longer Recommended as First-Line HIV Therapy

DHHS: Atripla No Longer Recommended as First-Line HIV Therapy

, by Emily Newman

The U.S. Department of Health and Human Services recently demoted the widely-used HIV combination pill Atripla from first-line HIV therapy recommendations, not because of a problem with the drug itself, but because of the changing landscape in HIV treatment. Read More